- $576.56m
- $235.12m
- 46
- 29
- 28
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.68 | ||
| Price to Tang. Book | 1.68 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.85% | ||
| Return on Equity | -31.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Directors
- Esther Van Den Boom CFO
- John Healy GCN
- Dan Bensen EXO
- Todd Harris EXO
- Robert Hudkins EXO
- Ronald Swanson EXO
- Rehan Verjee DRC
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 2nd, 2018
- Public Since
- September 15th, 2021
- No. of Shareholders
- 33
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 53,089,957
- Address
- 2656 State Street, CARLSBAD, 92008
- Web
- https://tyra.bio/
- Phone
- +1 6197284760
- Contact
- Amy Conrad
- Auditors
- Ernst & Young LLP
Upcoming Events for TYRA
Tyra Biosciences Inc Annual Shareholders Meeting
Tyra Biosciences Inc Annual Shareholders Meeting
Q2 2025 Tyra Biosciences Inc Earnings Release
Similar to TYRA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Tyra Biosciences share price?
As of Today at 23:51 UTC, shares in Tyra Biosciences are trading at $10.86. This share price information is delayed by 15 minutes.
How has the Tyra Biosciences share price performed this year?
Shares in Tyra Biosciences last closed at $10.86 and the price had moved by -41.39% over the past 365 days. In terms of relative price strength the Tyra Biosciences share price has underperformed the S&P500 Index by -47.15% over the past year.
What are the analyst and broker recommendations for Tyra Biosciences?
The overall consensus recommendation for Tyra Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tyra Biosciences dividend yield?
Tyra Biosciences does not currently pay a dividend.
Does Tyra Biosciences pay a dividend?
Tyra Biosciences does not currently pay a dividend.
When does Tyra Biosciences next pay dividends?
Tyra Biosciences does not currently pay a dividend.
How do I buy Tyra Biosciences shares?
To buy shares in Tyra Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tyra Biosciences?
As of the previous close price of $10.86, shares in Tyra Biosciences had a market capitalisation of $576.56m.
Where are Tyra Biosciences shares listed?
Here are the trading details for Tyra Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TYRA
What kind of share is Tyra Biosciences?
Based on an overall assessment of its quality, value and momentum Tyra Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tyra Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Tyra Biosciences is $30.43. That is 180.2% above the last closing price of $10.86.
Analysts covering Tyra Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.17 for the next financial year.
Find out moreWhat is the trend in the Tyra Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tyra Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -33.44%.
As of the last closing price of $10.86, shares in Tyra Biosciences were trading -33.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tyra Biosciences PE Ratio?
The Tyra Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tyra Biosciences?
Tyra Biosciences' management team is headed by:
- Esther Van Den Boom - CFO
- John Healy - GCN
- Dan Bensen - EXO
- Todd Harris - EXO
- Robert Hudkins - EXO
- Ronald Swanson - EXO
- Rehan Verjee - DRC